GenScript COVID-19 virus antigens and antibodies

From diagnostics to drug discovery and vaccine development, GenScript has developed a comprehensive range of products that scientists may use to accelerate COVID-19 research and development. As the virus continues to mutate, much focus is now being placed on the variants due to their more infectious nature. GenScript provides both wild-type and variant versions (eg, Alpha, Beta, Gamma, Delta, Lambda, etc) of the SARS-CoV-2 protein, and these have been validated to bind to the human ACE2 receptor and may serve as antigens in both ELISA assays and Western Blot.

To complement these antigens, the company also offers COVID-19 antibodies that are specific to the SARS-CoV-2 nucleocapsid protein or the SARS-CoV-2 spike protein. The SARS-CoV-2 Spike Neutralizing Antibody Standard (A02087) is particularly useful in the assessment and development of assays for the detection and quantitation of SARS-CoV-2 neutralising antibodies. Neutralising antibodies are known to be more effective than regular binding antibodies in decreasing the SARS-CoV-2 viral infection of cells. The antibody standard binds to multiple neutralising epitopes in the receptor binding domain, and may be used in ELISA assays and in performing neutralisation tests.